Tradestie Institutional Equity Comparison Engine

SRZN vs NBP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NBP Overall Edge

NBP Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to NBP (NBP) driven by superior Valuation, Growth & Margin while SRZN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus NBP at 2.7x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against NBP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner NBP
SRZN N/M vs NBP 2.7x Fwd P/E
Growth & Margin Winner NBP
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs +0.0%
Momentum & Technical Winner SRZN
1Y +170.6% vs -81.0% ยท 52W Pos 80% vs 0%
Options & Structure Winner SRZN
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.80
+3.76% 1D
Market Cap $603.7M
1M Return +39.93%
1Y Return +170.63%
Forward P/E N/M
Unified AI Score
32.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 64.0 Mom 40.0
NBP US Equity
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap $96.3M
1M Return -37.04%
1Y Return -80.98%
Forward P/E 2.7x
Unified AI Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +170.63% NBP -80.98% Spread: +251.61 pp (SRZN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SRZN TTM Op. Margin: -485.4% NBP TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs NBP. Trailing 12-month operating profitability (SRZN -485.4% vs NBP 0.0%) and valuation multiples (SRZN N/M vs NBP 2.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (4) vs NBP (5)
Institutional Metric SRZN NBP Criterion Row Winner
Market Capitalization Scale $603.7M $96.3M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M 2.7x Lower Multiple NBP
Forward P/E Ratio Valuation N/M 2.7x Lower Multiple NBP
Revenue Growth (YoY) Growth +408.6% +0.0% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% 0.0% Higher Margin NBP
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -59.1% Higher ROE NBP
52-Week Range Position Momentum 80% ($12โ€“$38) 0% ($1โ€“$5) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.21ฮฒ ยท 62% Vol 1.66ฮฒ ยท 81% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 32.8 / 100 (SELL) 51.9 / 100 (HOLD) Higher Composite NBP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs NBP Buy Guide
SRZN CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NBP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NBP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor NBP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.